Influenza and Meningococcal Vaccinations Are Effective in Healthy Subjects Treated with the Interleukin-1β-Blocking Antibody Canakinumab: Results of an Open-Label, Parallel Group, Randomized, Single-Center Study
Authors:
- 1 December 2010
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (12) , 1952-1957
Abstract
The objective of this study was to evaluate the efficacy of influenza and meningococcal vaccines in healthy subjects exposed to the anti-interleukin-1β (anti-IL-1β) monoclonal antibody canakinumab. This was an open-label, parallel group, randomized, single-center study of healthy subjects (aged 18 to 45 years). At baseline, antibody (Ab) titers were measured and subjects were randomized (1:1) to a single 300-mg canakinumab dose administered subcutaneously (s.c.) or received no treatment (control group). After 2 weeks, subjects were treated with inactivated, unadjuvanted influenza and conjugated group C meningococcal (MenC) vaccines, administered intramuscularly (i.m.). The primary efficacy variable was the response (≥2-fold increase in Ab titer in ≥2 of 3 influenza virus strains) after 4 weeks in subjects treated with canakinumab compared to the control group. Secondary efficacy variables were the antibody response to vaccines at different thresholds and time points. Fifty-one of 112 subjects screened were randomized to canakinumab ( n = 25) or the control group ( n = 26). Antibody responses to vaccinations measured against different influenza virus strains and one MenC strain at 4 weeks were comparable in the canakinumab and control groups. The primary efficacy variable, the response to influenza vaccination (≥2-fold increase in Ab titer in ≥2 of 3 serotypes) at 4 weeks, was shown in 24/25 subjects in the canakinumab group compared to 25/25 subjects in the control group. Antibody responses remained comparable in the two groups at the different time points assessed. Headache was the most frequently reported adverse event. No deaths or serious adverse events were reported during the study. We concluded that a single dose of 300 mg canakinumab s.c. does not affect the induction or persistence of antibody responses after vaccination with unadjuvanted influenza or alum-adjuvanted MenC vaccines in healthy subjects.Keywords
This publication has 24 references indexed in Scilit:
- Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: Safety and immunogenicityClinical Immunology, 2010
- In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromesJournal of Experimental Medicine, 2009
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals of the Rheumatic Diseases, 2009
- Alum adjuvanticity: Unraveling a century old mysteryEuropean Journal of Immunology, 2008
- Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvantsNature, 2008
- Vaccines: Vaccination in Patients with Chronic Rheumatic or Autoimmune DiseasesClinical Infectious Diseases, 2008
- Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjectsArthritis Research & Therapy, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockersAnnals of the Rheumatic Diseases, 2006
- Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based studyArthritis & Rheumatism, 2002